Uro SIA
- Address
- lock Available on a paid plan
Uro SIA - Prostate Cancer Research Center
Uro SIA is a specialized urology research facility dedicated to advancing treatment options for patients with prostate cancer. The center focuses on investigating novel therapeutic approaches for advanced prostate malignancies, with particular emphasis on hormonal therapies and combination treatment strategies.
- Metastatic hormone-sensitive prostate cancer treatment protocols
- Combination androgen deprivation therapy studies
- Next-generation androgen receptor inhibitor research
The center's clinical research program evaluates innovative pharmaceutical interventions, including darolutamide combined with androgen deprivation therapy (ADT), aimed at improving radiographic progression-free survival in men with metastatic hormone-sensitive prostate cancer (mHSPC). Through rigorous controlled trials, Uro SIA contributes to the development of evidence-based therapeutic strategies that may extend the time before disease progression in patients with advanced prostate cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uro SIA
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC). | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Feb 2021 | Nov 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Darolutamide | 1 | Unknown | 2021-02-22 | 2021-02-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.